reversed-phase chromatography is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-09. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
In addition, there were hundreds of thousands of part-time employees and informers in various Syrian intelligence departments. According to estimates, there was one member of various branches of the Ba'athist secret police for every 158 citizens, which was said to be one of the largest ratios in the world. The general intelligence, political security, and military intelligence divisions of the Ba'athist secret police had several branches in all governorates controlled by the Assad regime, where they were all headquartered in Damascus. With state impunity granted by the Assad regime, officers of the Mukhabarat wielded pervasive influence over local bodies, civil associations and bureaucracy, where they played a major role in shaping Ba'athist administrative decisions. Additionally, intense factional rivalries and power struggles existed among various branches of the secret police. Several academics have described the military, bureaucratic, and secret police apparatus of the Ba'athist state as constituting a pyramidal socio-political structure with an Orwellian surveillance system designed to neutralize independent civic activities and political dissent from its very onset. During Ba'athist rule, Syria was one of the five countries listed on Reporters Without Borders' list of "State Enemies of the Internet" in March 2013, which was a list of countries ruled by governments that perpetrate pervasive surveillance of news providers that resulted in harsh restrictions on access to information and personal lives.
From 1996 to 2002 additional functionality was included, from wireless networking and georeferencing of samples, to the adoption of XML standards and Internet purchasing. As of 2012, some LIMS have added additional characteristics such as clinical functionality, electronic laboratory notebook (ELN) functionality, as well a rise in the software as a service (SaaS) distribution model.
== General biochemistry concepts == Major categories of bio-compounds: Carbohydrates : sugar – disaccharide – polysaccharide – starch – glycogen Lipids : fatty acid – fats – essential oils – oils – waxes – cholesterol Nucleic acids : DNA – RNA – mRNA – tRNA – rRNA – codon – adenosine – cytosine – guanine – thymine – uracil Proteins : amino acid – glycine – arginine – lysine peptide – primary structure – secondary structure – tertiary structure – conformation – protein folding Chemical properties: molecular bond – covalent bond – ionic bond – hydrogen bond – ester – ethyl molecular charge – hydrophilic – hydrophobic – polar pH – acid – alkaline – base oxidation – reduction – hydrolysis Structural compounds: In cells: flagellin – peptidoglycan – myelin – actin – myosin In animals: chitin – keratin – collagen – silk In plants: cellulose – lignin – cell wall Enzymes and enzyme activity: enzyme kinetics – enzyme inhibition proteolysis – ubiquitin – proteasome kinase – dehydrogenase Membranes : fluid mosaic model – diffusion – osmosis phospholipids – glycolipid – glycocalyx – antigen – isoprene ion channel – proton pump – electron transport – ion gradient – antiporter – symporter – quinone – riboflavin Biomolecule (list) Biomolecular engineering Biomolecular structure Multi-state modeling of biomolecules Energy pathways : pigments : chlorophyll – carotenoids – xanthophyll – cytochrome – phycobilin – bacteriorhodopsin – hemoglobin – myoglobin – absorption spectrum – action spectrum – fluorescence Photosynthesis : light reaction – dark reaction Fermentation : Acetyl-CoA – lactic acid Cellular respiration : Adenosine triphosphate (ATP) – NADH – pyruvate – oxalate – citrate Chemosynthesis Regulation hormones : auxin signal transduction – growth factor – transcription factor – protein kinase – SH3 domain Malfunctions : tumor – oncogene – tumor suppressor gene Receptors : Integrin – transmembrane receptor – ion channel Techniques : electrophoresis – chromatography – mass spectrometry – x-ray diffraction – Southern blot – fractionation – Gram stain – Surface Plasmon Resonance – Microscale Thermophoresis
Sources: en.wikipedia.org
=== Videos === "Time Thief" (1990) "Half-Life, Remembered" (1990) "Kinky Love" (1991) "Blue Flower" (1992) "Throwing Back the Apple" (1992) "Fine Friend" (1994) "Angel (Will You Be My)" (1994) "Sight of You" (2020)
== Contraindications == Hypersensitivity to dalbavancin can occur, causing issues such as skin reactions or anaphylaxis. Caution is advised for patients with known hypersensitivity to other glycopeptides. There is currently no data on cross-reactivity between dalbavancin and vancomycin.
=== Sources === Peng, Dixian; Shu, Guofan (1990). 刘文辉史话 [Historical Tales of Liu Wenhui] (in Chinese). Chengdu: Sichuan University Press. ISBN 7-5614-0298-8. Lawson, Joe (2011). Xikang: Han Chinese in Sichuan's Western Frontier, 1905-1949 (PhD thesis). University of Wellington. doi:10.26686/wgtn.17011421. Kim, Hee-shin (2007). "남경국민정부시기 劉文輝와 川康 政治" [Liu Wenhui and the Politics of Sichuan and Xikang during the Nationalist Government Period]. 中國學報. 56: 311–341 – via Korea Citation Index. Leibold, James (2007). Reconfiguring Chinese Nationalism: How the Qing Frontier and its Indigenes Became Chinese. Basingstoke: Palgrave Macmillan. ISBN 978-1-4039-7479-2.
Sources: en.wikipedia.org
=== TRPV1 === AM404 is also a TRPV1 agonist and inhibitor of cyclooxygenase COX-1 and COX-2, thus attenuating prostaglandin synthesis. The anticonvulsant action of AM404 is mediated through TRPV1, according to Suemaru et al. (2018), rebutting a previous explanation involving CB1 receptors.
=== Manufacturing === In 2017, the total output (gross value added) in the manufacturing industry amounted to 14.4% of total output in Denmark. 325,000 people or a little less than 12% of all employed persons worked in manufacturing (including utilities, mining and quarrying) in 2016. Main sub-industries are manufacture of pharmaceuticals, machinery, and food products.
In his (August 1962) Report to the National Research Council of the National Academy of Sciences (AP.2), Archie Palmer reported that, of the 945 US "higher education institutions" he had surveyed, 349 had either "formulated and adopted a formalized research and patent policy", or were observing "a generally accepted practice with respect to the handling of research and patent matters", whilst the remaining 596 (which, he observed, conducted "little or no scientific or technological research") had "no formalized research or patent policies". In 1965, 96 US patents were granted to 28 "US universities or related institutions"; in 1992, 1500 US patents were granted to more than 150 "US universities or related institutions" (RH.2, p. 119). In 2025, the (formerly reluctant) University of California had been granted 571 patents, making the university's total "over 6,800 active patents" (JB.1). According to the economists Stanley Engerman and Gavin Wright (SE.1), (a) until 1933 there were more US patents issued to individuals than those issued to corporations, (b) by 1950 the ratio was 50:50, (c) by 1998, whilst the number of US patents issued to individual inventors remained more or less the same, (i.e., 10,000–15,000 per annum), they only represented approx. 10% of the number of patents issued.
== Enzyme structure == The enzyme can be found in a monofunctional form, in some bacteria and yeast. Structural analysis of the yeast monofunctional enzyme indicates that the enzyme is a dimer composed of three distinct regions; an N-terminal nucleotide-binding domain, a short central dimerisation region, and a C-terminal catalytic domain. The N-terminal domain forms a modified Rossmann fold, while the catalytic domain forms a novel alpha-beta mixed sheet. The enzyme can also be found in a bifunctional form consisting of an N-terminal aspartokinase domain and a C-terminal homoserine dehydrogenase domain, as found in bacteria such as Escherichia coli and in plants. The bifunctional aspartokinase-homoserine dehydrogenase (AK-HSD) enzyme has a regulatory domain that consists of two subdomains with a common loop-alpha helix-loop-beta strand loop-beta strand motif. Each subdomain contains an ACT domain that allows for complex regulation of several different protein functions. The AK-HSD gene codes for aspartate kinase, an intermediate domain (coding for the linker region between the two enzymes in the bifunctional form), and finally the coding sequence for homoserine dehydrogenase. As of late 2007, 4 structures have been solved for this class of enzymes, with PDB accession codes PDB: 1EBF, PDB: 1EBU, PDB: 1Q7G, and PDB: 1TVE.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.